Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

References

• LymanGHDaleDCCrawfordJIncidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practicesJ Clin Oncol200321244524453114673039
   PubMed Web of Science ®Google Scholar
• KudererNMMeta-analysis of randomized controlled trials of granulocyte colony-stimulating factor prophylaxis in adult cancer patients receiving chemotherapyCancer Treat Res201115712714321052954
   PubMedGoogle Scholar
• KudererNMLymanGHPersonalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapyJ Natl Cancer Inst20111031291091321670422
   PubMedGoogle Scholar
• KomrokjiRSLymanGHThe colony-stimulating factors: use to prevent and treat neutropenia and its complicationsExpert Opin Biol Ther20044121897191015571452
   PubMed Web of Science ®Google Scholar
• RiaRRealeAMoschettaMDammaccoFVaccaANeutropenia and G-CSF in lymphoproliferative diseasesHematology201318313113723321273
   PubMed Web of Science ®Google Scholar
• PizzoPAMeyersJInfections in the cancer patientsDevitaVTJrHellmanSRosenbergSACancer: Principles and Practice of Oncology3rd edPhiladelphia, PAJB Lippincott Co198920892098
   Google Scholar
• HongWSClinical effects of Gracin (recombinant human granulocyte-colony stimulating factor) on leucopenia induced by VAP chemotherapy in patients with lung cancerKorean J BRM1993315566
   Google Scholar
• WallerCFSemiglazovVFTjulandinSBentsionDChanSChallandRA phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancerOnkologie2010331050451120926897
   PubMedGoogle Scholar
  ErratumOnkologie20103312725
   Google Scholar
• AbrahamITharmarajahSMacDonaldKClinical safety of biosimilar recombinant human granulocyte colony-stimulating factorsExpert Opin Drug Saf201312223524623419039
   PubMed Web of Science ®Google Scholar
• VerpoortKMöhlerTMA non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centreTher Adv Med Oncol20124628929323118804
   PubMed Web of Science ®Google Scholar
• PaniLMontillaSPimpinellaGBertini MalgariniRBiosimilars: the paradox of sharing the same pharmacological action without full chemical identityExpert Opin Biol Ther201313101343134623805906
   PubMed Web of Science ®Google Scholar
• Rinaudo-GaujousMPaulSTedescoEDGeninCRoblinXPeyrin-BirouletLReview article: biosimilars are the next generation of drugs for liver and gastrointestinal diseasesAliment Pharmacol Ther201338891492424001128
   PubMed Web of Science ®Google Scholar
• del GiglioAEniuAGanea-MotanDTopuzovELubenauHXM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapyBMC Cancer2008833219014494
   PubMed Web of Science ®Google Scholar
• GatzemeierUCiuleanuTDediuMGanea-MotanELubenauHDel GiglioAXM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapyJ Thorac Oncol20094673674019404210
   PubMed Web of Science ®Google Scholar
• EngertAdel GiglioABiasPLubenauHGatzemeierUHeigenerDIncidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin’s lymphomaOnkologie2009321059960419816079
   PubMedGoogle Scholar
• EngertAGriskeviciusLZyuzginYLubenauHdel GiglioAXM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapyLeuk Lymphoma200950337437919347726
   PubMed Web of Science ®Google Scholar
• GómezHHidalgoMCasanovaLRisk factors for treatment-related death in elderly patients with aggressive non-Hodgkin’s lymphoma: results of a multivariate analysisJ Clin Oncol1998166206520699626205
   PubMed Web of Science ®Google Scholar
• LymanGHMorrisonVADaleDCOPPS Working GroupANC Study GroupRisk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapyLeuk Lymphoma200344122069207614959849
   PubMed Web of Science ®Google Scholar
• LymanGHDelgadoDJRisk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphomaCancer200398112402240914635075
   PubMed Web of Science ®Google Scholar
• CrawfordJDaleDCKudererNMRisk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practiceJ Natl Compr Canc Netw20086210911818319047
   PubMedGoogle Scholar
• CrawfordJDaleDCLymanGHChemotherapy-induced neutropenia: risks, consequences, and new directions for its managementCancer2004100222823714716755
   PubMed Web of Science ®Google Scholar
  ReviewErratumCancer2004100919931994
   Google Scholar
• PettengellRSchwenkglenksMLeonardRImpact of Neutropenia in Chemotherapy-European Study Group (INC-EU)Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia studySupport Care Cancer200816111299130918351398
   PubMed Web of Science ®Google Scholar
• VoogEBienvenuJWarzochaKFactors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor systemJ Clin Oncol200018232533110637246
   PubMed Web of Science ®Google Scholar
• WunderlichAKloessMReiserMPracticability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin’s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)Ann Oncol200314688189312796026
   PubMed Web of Science ®Google Scholar
• LymanGHKudererNAgboolaOBalducciLEvidence-based use of colony-stimulating factors in elderly cancer patientsCancer Control200310648749914652525
   PubMedGoogle Scholar
• LymanGHKudererNMCrawfordJPredicting individual risk of neutropenic complications in patients receiving cancer chemotherapyCancer201111791917192721509769
   PubMed Web of Science ®Google Scholar
• CarrJGuideline for the Use of Granulocyte-Colony Stimulating Factor (G-CSF) in Adult PatientsAvon, Somerset and Wiltshire Cancer Services20129
   Google Scholar